Skip to main content

Table 1 Baseline chacteristics of enrolled studies

From: Meta-analysis of serum C-reactive protein and cartilage oligomeric matrix protein levels as biomarkers for clinical knee osteoarthritis

Study

Design

Number

Age (years)

Follow-up

area

Fernandes, 2007

Case control

KOA:75 Control: 40

KOA:56.6 ± 7.6; Control: 53.8 ± 8.5

NA

Brazil

Senolt, 2005

Case control

KOA:38

Control: 38

KOA:64.1 ± 10.1; Control: 58.3 ± 9.1

NA

USA

Wakitani, 2007

Case control

KOA:31

Control: 24

KOA:20–80; Control: 23–52

NA

Japan

Li, 2012

Case control

KOA:115

Control: 35

KOA:55 ± 13.2; Control:53 ± 12.53

2–3 years

China

Engstrom, 2009

population-based cohort

5171

57.5 + 5.9

12.4 years

Sweden

Zhang, 2015

Case control

Control: 20

KOA: 20

Control:56.3 ± 7.9; KOA: 59.2 ± 8.3

NA

China

Sowers, 2002

cohort

1025

42.9 ± 0.1

2.5 years

USA

Kerkhof,2010

Case control

KOA: 210; Control: 1360

≥55 years

NA

Netherlands

Haghighian,2014

Case control

23

58.27 ± 7.84

2 months

Iran

Ramirez, 2014

cohort

186

61 ± 7.3

2 years

Netherlands

Nielsen, 2014

Case control

281

40–80

NA

Denmark

Scorei, 2011

Case control

15

67.6 (5.5)

2 weeks

Romania

Stannus, 2012

cohort study

KOA:35; Control:114

KOA:63.2 ± 6.9 Control: 61.5 ± 6.7

5 years

Australia

Hosnijeh, 2016

population-based prospective cohort

1335

65.2 (8.43)

5-year

Netherlands

  1. KOA knee osteoarthritis